PROSTATE CANCER

Men must be entitled to PCa screening, treatment choiceThe following letter was sent to Urology Times in response to a previously published letter to the editor, "Dear USPSTF: Don't discount value of PSA in men 70+."
Uro Pipeline: UTI vaccine receives fast track designation from FDAOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Side effects of modern PCa treatments comparedDespite technological advances in treatment for localized prostate cancer, men continue to experience clinically meaningful side effects that affect quality of life, according to an examination of data from a prospective population-based cohort study.
Life vs. quality of life: A delicate balance
Metformin may improve advanced prostate Ca outcomesMetformin may act synergistically with androgen deprivation therapy to improve outcomes for men with advanced prostate cancer, according to findings of an observational study presented at the AUA annual meeting in Boston.
How prostate cancer genetics will change front-line careIn this interview, Leonard G. Gomella, MD, provides an update on prostate cancer genetics, discusses the recent Prostate Cancer International Consensus Conference, and outlines why urologists should conduct more extensive family histories of their prostate cancer patients.
New products: Holmium laser increases stone ablation volumeOther products discussed include cancer tests, an app to connect patients with specialists, a revenue management system, and more
Higher reclassification rate seen with saturation biopsyTransrectal saturation biopsy resulted in higher rates of disease reclassification compared with magnetic resonance (MR) fusion biopsy plus extended sextant prostate biopsy in patients with low-risk prostate cancer on active surveillance.
Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drugOther pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.
BMI predicts post-RP metastasis, PCa mortalityFindings from a recent study also suggest that obesity may be a factor to consider for men with prostate cancer deciding between active surveillance and definitive treatment.

Poll